Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
2.
Int. braz. j. urol ; 47(5): 982-988, Sept.-Oct. 2021. tab
Artículo en Inglés | LILACS | ID: biblio-1286803

RESUMEN

ABSTRACT Purpose: To compare the effects of tadalafil, tamsulosin, and placebo as a medical expulsive therapy (MET) for distal ureteral calculi. Materials and Methods: This prospective randomized double-blind clinical trial was conducted on 132 renal colic patients with distal ureteric stones (≤10mm) over a period of 12 months. Patients were randomly divided into three groups. Patients in group A received tamsulosin 0.4mg, in group B received tadalafil 10mg, and in group C received placebo. Therapy was given for a maximum of 4 weeks. The rate of stone expulsion, duration of stone expulsion, the dose and the duration of nonsteroidal anti-inflammatory drugs (NSAIDs), analgesic use, and adverse effects of drugs were recorded. Results: Demographic profiles were comparable between the 3 groups. Although the stone expulsion rate in group A (72.7%) was higher in comparison to group B(63.6%) and group C(56.8%), it was not considered statistically significant (P=0.294). Shorter mean time to stone expulsion was significantly observed in group A (17.75±75), than group B(21.13±1.17) and group C(22.25±1.18) (P=0.47). The mean number of analgesic use was 9.8±5.09 days in group A, 14.6±7.9 days in group B, and 12.6±22.25 days in group C, this difference was significant (P=0.004). The analgesic requirement (doses of NSAIDs and pethidine) in group A was significantly lower than other groups (P<0.05). Also, patients in group A reported fewer headaches compared to other groups (P=0.011). Conclusion: Tamsulosin as medical expulsive therapy is more effective for distal ureteric stones with less need for analgesics and less stone expulsion time than tadalafil.


Asunto(s)
Humanos , Cálculos Ureterales/tratamiento farmacológico , Sulfonamidas/uso terapéutico , Estudios Prospectivos , Resultado del Tratamiento , Tadalafilo/uso terapéutico , Tamsulosina/uso terapéutico
3.
Int. braz. j. urol ; 47(4): 747-752, Jul.-Aug. 2021. tab
Artículo en Inglés | LILACS | ID: biblio-1286764

RESUMEN

ABSTRACT Purpose: To describe the otorhinolaryngological adverse effects of the main drugs used in urological practice. Materials and Methods: A review of the scientific literature was performed using a combination of specific descriptors (side effect, adverse effect, scopolamine, sildenafil, tadalafil, vardenafil, oxybutynin, tolterodine, spironolactone, furosemide, hydrochlorothiazide, doxazosin, alfuzosin, terazosin, prazosin, tamsulosin, desmopressin) contained in publications until April 2020. Manuscripts written in English, Portuguese, and Spanish were manually selected from the title and abstract. The main drugs used in Urology were divided into five groups to describe their possible adverse effects: alpha-blockers, anticholinergics, diuretics, hormones, and phosphodiesterase inhibitors. Results: The main drugs used in Urology may cause several otorhinolaryngological adverse effects. Dizziness was most common, but dry mouth, rhinitis, nasal congestion, epistaxis, hearing loss, tinnitus, and rhinorrhea were also reported and varies among drug classes. Conclusions: Most of the drugs used in urological practice have otorhinolaryngological adverse effects. Dizziness was most common, but dry mouth, rhinitis, nasal congestion, epistaxis, hearing loss, tinnitus, and rhinorrhea were also reported. Therefore, doctors must be aware of these adverse effects to improve adherence to the treatment and to minimize damage to the health of patients.


Asunto(s)
Humanos , Masculino , Hiperplasia Prostática , Preparaciones Farmacéuticas , Prazosina , Doxazosina , Agonistas alfa-Adrenérgicos , Tadalafilo , Tamsulosina
4.
Int. braz. j. urol ; 47(1): 23-35, Jan.-Feb. 2021. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1134321

RESUMEN

ABSTRACT Purpose: To evaluate the efficacy of adjunctive medical expulsive therapy (MET) with tamsulosin for the promotion of stone fragments clearance for repeated extracorporeal shock wave lithotripsy (ESWL). Materials and Methods: This meta-analysis was conducted by systematic search for randomized controlled trial (RCT) studies in PubMed/Medline, Scopus, Cochrane Library, Web of Science databases in January 2020, which compared tamsulosin with either placebo or non-placebo control for repeated ESWL. The primary endpoint was stone-free rate (SFR), the second endpoints were stone clearance time and complications. The quality assessment of included studies was performed by using the Cochrane System and Jadad score. Results: 7 RCTs were included in this meta-analysis. Tamsulosin provided higher SFR (for stones larger than 1cm, OR: 5.56, p=0.0003), except for patients with stones less than 1cm. For patients with renal stones (OR: 2.97, p=0.0005) or upper ureteral stones (OR: 3.10, p=0.004), tamsulosin can also provide a higher SFR. In addition, tamsulosin provided a shorter stone clearance time (WMD: −9.40, p=0.03) and lower pain intensity (WMD=-17.01, p <0.0001) and incidences of steinstrasse (OR: 0.37, p=0.0002). Conclusion: Adjunctive MET with tamsulosin is effective in patients with specific stone size or location that received repeated ESWL. However, no well-designed RCT that used computed tomography for the detection and assessment of residual stone fragments was found. More studies with high quality and the comparison between tamsulosin and secondary ESWL are needed in the future.


Asunto(s)
Humanos , Litotricia , Cálculos Renales/terapia , Cálculos Ureterales/tratamiento farmacológico , Sulfonamidas/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del Tratamiento , Tamsulosina
5.
Int. braz. j. urol ; 44(3): 600-607, May-June 2018. tab, graf
Artículo en Inglés | LILACS | ID: biblio-954052

RESUMEN

ABSTRACT Objectives: Apoptosis effect of oral alpha-blockers is known in the prostate. Apoptosis index of silodosin has not been proved, yet. Aims are to present apoptosis index of silodosin in prostate and to compare this with other currently used alpha-blocker's apoptosis indexes together with their clinical effects. Materials and Methods: Benign prostatic hyperplasia (BPH) patients were enrolled among those admitted to urology outpatient clinic between June 2014 and June 2015. Study groups were created according to randomly prescribed oral alpha-blocker drugs as silodosin 8mg (Group 1; n=24), tamsulosin 0.4mg (Group 2; n=30), alfuzosin 10mg (Group 3; n=25), doxazosin 8mg (Group 4; n=22), terazosin 5mg (Group 5; n=15). Pa- tients who refused to use any alpha-blocker drug were included into Group 6 as control group (n=16). We investigated apoptosis indexes of the drugs in prostatic tissues that were taken from patient's surgery (transurethral resection of prostate) and/or prostate biopsies. Immunochemical dyeing, light microscope, and Image Processing and Analy- sis in Java were used for evaluations. Statistical significant p was p<0.05. Results: There were 132 patients with mean follow-up of 4.2±2.1 months. Pathologist researched randomly selected 10 areas in each microscope set. Group 1 showed statisti- cal significant difference apoptosis index in immunochemical TUNEL dyeing and im- age software (p<0.001). Moreover, we determined superior significant development in parameters as uroflowmetry, quality of life scores, and international prostate symptom score in Group 1. Conclusions: Silodosin has higher apoptosis effect than other alpha-blockers in prostate. Thus, clinic improvement with silodosin was proved by histologic studies. Besides, static factor of BPH may be overcome with creating apoptosis.


Asunto(s)
Humanos , Masculino , Anciano , Anciano de 80 o más Años , Próstata/efectos de los fármacos , Próstata/patología , Hiperplasia Prostática/patología , Hiperplasia Prostática/tratamiento farmacológico , Apoptosis/efectos de los fármacos , Antagonistas de Receptores Adrenérgicos alfa 1/farmacología , Quinazolinas/farmacología , Valores de Referencia , Sulfonamidas/farmacología , Factores de Tiempo , Biopsia , Prazosina/análogos & derivados , Prazosina/farmacología , Inmunohistoquímica , Proyectos Piloto , Estudios Retrospectivos , Resultado del Tratamiento , Antígeno Prostático Específico/sangre , Doxazosina/farmacología , Tamsulosina , Indoles/farmacología , Persona de Mediana Edad
6.
National Journal of Andrology ; (12): 247-253, 2018.
Artículo en Chino | WPRIM | ID: wpr-689768

RESUMEN

<p><b>Objective</b>To investigate the therapeutic effects of commonly used selective α-adrenergic receptor antagonists (α-ARA) on benign prostatic hyperplasia (BPH).</p><p><b>METHODS</b>PubMed, Embase and CNKI databases were searched for the literature about selective α-ARAs for the treatment of BPH and the information was extracted on the common adverse reactions in the course of treatment. Multivariate meta-analysis was conducted to investigate the therapeutic effects of different α-ARAs.</p><p><b>RESULTS</b>The total rates of adverse effects of silodosin and tamsulosin were the highest, 51.9% and 34.0% respectively, with the highest incidences of headache (38.3%), weakness (23.6%) and dizziness (17.5%). Besides, tamsulosin ranked the first in inducing sexual dysfunction of the male patients with BPH (70.4%).</p><p><b>CONCLUSIONS</b>Doxazosin is preferable as the first-choice treatment of BPH for its therapeutic effect and improvement of the patient's quality of life. Silodosin and tamsulosin, however, can be selectively used according to the patient's specific tolerance to different adverse effects.</p>


Asunto(s)
Humanos , Masculino , Antagonistas Adrenérgicos alfa , Usos Terapéuticos , Doxazosina , Usos Terapéuticos , Indoles , Usos Terapéuticos , Metaanálisis en Red , Hiperplasia Prostática , Quimioterapia , Calidad de Vida , Disfunciones Sexuales Fisiológicas , Tamsulosina , Usos Terapéuticos
7.
National Journal of Andrology ; (12): 1107-1110, 2017.
Artículo en Chino | WPRIM | ID: wpr-812825

RESUMEN

Objective@#To study the therapeutic effect of Lamiophlomis Rotata Capsule (LRC) in the treatment of type ⅢB prostatitis.@*METHODS@#We randomly divided 225 patients with type ⅢB prostatitis into an experimental group (n =125) and a control group (n =120), the former treated orally with LRC at 3 capsules tid while the latter with tamsulosin hydrochloride sustained-release capsules at 0.2 mg qd, both for 4 weeks. We compared the therapeutic effects between the two groups of patients based on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) obtained before, immediately after and at 4 weeks after medication.@*RESULTS@#A total of 120 patients completed the treatment in the experimental group, which showed remarkable decreases as compared with the baseline in the pain score (5.30 ± 1.23 vs 14.68 ± 1.51, P0.05). The experimental group achieved even markedly lower scores than the controls in the pain symptom (5.30 ± 1.23 vs 13.67 ± 1.49, P<0.05), QoL (6.46 ± 0.93 vs 7.47 ± 0.88, P<0.05) and total NIH-CPSI (17.50 ± 2.77 vs 25.77 ± 2.01, P<0.05) but a higher urination symptoms score than the latter after medication (7.16 ± 1.04 vs 5.68 ± 1.34, P<0.05). At 4 weeks after drug withdrawal, the experimental group also showed significantly lower scores of the pain symptom (7.23 ± 1.03), QoL (6.58 ± 0.87) and total NIH-CPSI (22.18 ± 2.03) than the baseline (all P<0.05) and those in the control group (14.14 ± 0.98, 8.12 ± 0.72 and 26.89 ± 1.67) (all P<0.05). Apart from dizziness in 2 of the patients, who gave up medication halfway, no other obvious adverse reactions were observed during the experiment.@*CONCLUSIONS@#Lamiophlomis Rotata Capsule deserves to be recommended for the treatment of type ⅢB prostatitis for its safety and effectiveness in reducing the pain and improving the life quality of the patients.


Asunto(s)
Humanos , Masculino , Cápsulas , Enfermedad Crónica , Preparaciones de Acción Retardada , Medicamentos Herbarios Chinos , Usos Terapéuticos , Manejo del Dolor , Prostatitis , Quimioterapia , Patología , Calidad de Vida , Tamsulosina , Usos Terapéuticos , Micción , Agentes Urológicos , Usos Terapéuticos
8.
National Journal of Andrology ; (12): 164-168, 2017.
Artículo en Chino | WPRIM | ID: wpr-812792

RESUMEN

Objective@#To study the safety and efficacy of Bushen Daozhuo Granules (BDG) in the treatment of type Ⅲ prostatitis.@*METHODS@#This multicenter randomized controlled clinical trial included 478 patients with type Ⅲ prostatitis, 290 in the trial group and 188 as controls, the former treated with BDG at 200 ml bid and the latter with tamsulosin hydrochloride sustainedrelease capsules at 0.2 mg qd, both for 4 weeks. Before treatment, after 4 weeks of medication, and at 4 weeks after drug withdrawal, we obtained the NIH Chronic Prostatitis Symptom Index (NIHCPSI) scores and compared the safety and effectiveness rate between the two groups of patients.@*RESULTS@#Compared with the baseline, the NIHCPSI score was markedly decreased in the control group after 4 weeks of medication (21.42 ± 4.02 vs 15.67 ± 3.65, P 0.05), while the NIHCPSI score in the trial group was remarkably lower than the baseline both after 4 weeks of medication and at 4 weeks after drug withdrawal (10.92 ± 2.06 and 12.91 ± 2.64 vs 21.58 ± 3.67, P < 0.05). The trial group exhibited both a higher rate of total effectiveness and safety than the control (P < 0.05).@*CONCLUSIONS@#BDG is safe and effective for the treatment of type Ⅲ prostatitis.


Asunto(s)
Humanos , Masculino , Cápsulas , Enfermedad Crónica , Preparaciones de Acción Retardada , Medicamentos Herbarios Chinos , Usos Terapéuticos , Prostatitis , Quimioterapia , Patología , Sulfonamidas , Usos Terapéuticos , Tamsulosina , Resultado del Tratamiento , Agentes Urológicos , Usos Terapéuticos
9.
Int. braz. j. urol ; 42(3): 578-584, tab
Artículo en Inglés | LILACS | ID: lil-785721

RESUMEN

ABSTRACT Purpose Postoperative urinary retention (POUR) is one of the most common complications after surgical procedures under spinal anaesthesia. Recent studies have shown the beneficial effects of alpha-adrenergic blockers in preventing POUR. The aim of this prospective study was to investigate and compare the prophylactic effects of tamsulosin and alfuzosin on POUR after urologic surgical procedures under spinal anaesthesia. Materials and Methods A total of 180 males who underwent elective urologic surgery were included in this study. The patients were randomly allocated into three Groups. The Group I received placebo. Patients in Group II were given 0.4mg of tamsulosin orally 14 and 2 hours before surgery. Patients in Group III were given 10mg of alfuzosin ER orally 10 and 2 hours before surgery. All patients were closely followed for 24 hours postoperatively and their episodes of urinary retentions were recorded. Results There were 60 patients in each Group. Their mean age was 35.95±15.16 years. Fifteen patients in Group I (25%), 3 patients in Group II (5%) and 4 patients in Group III (6.7%) required catheterization because of urinary retention. In tamsulosin group and alfuzosin group, there were a significantly lower proportion of patients with POUR compared with the placebo Group (p=0.002 and p=0.006). The beneficial effects of tamsulosin and alfuzosin on POUR were similar between both Groups (p=0.697). Conclusion This study suggests that the use of prophylactic tamsulosin or alfuzosin can reduce the incidence of urinary retention and the need for catheterization after urologic surgical procedures under spinal anaesthesia.


Asunto(s)
Humanos , Masculino , Adolescente , Adulto , Anciano , Adulto Joven , Quinazolinas/uso terapéutico , Sulfonamidas/uso terapéutico , Procedimientos Quirúrgicos Urológicos Masculinos/efectos adversos , Retención Urinaria/prevención & control , Antagonistas de Receptores Adrenérgicos alfa 1/uso terapéutico , Profilaxis Pre-Exposición/métodos , Anestesia Raquidea/efectos adversos , Complicaciones Posoperatorias/prevención & control , Factores de Tiempo , Cateterismo Urinario , Estudios Prospectivos , Reproducibilidad de los Resultados , Análisis de Varianza , Retención Urinaria/etiología , Resultado del Tratamiento , Tamsulosina , Persona de Mediana Edad
10.
Int. braz. j. urol ; 42(1): 101-106, Jan.-Feb. 2016. tab
Artículo en Inglés | LILACS | ID: lil-777316

RESUMEN

ABSTRACT Objective To evaluate the clinical efficiency of alpha1-adrenergic antagonists on stentless ureteroscopic lithotripsy treating uncomplicated lower ureteral stones. Materials and Methods From January 2007 to January 2013, 84 patients who have uncomplicated lower ureteral stones treated by ureteroscopic intracorporeal lithotripsy with the holmium laser were analyzed. The patients were divided into two groups, group A (44 patients received indwelled double-J stents) and group B (40 patients were treated by alpha1-adrenergic antagonists without stents). All cases of group B were treated with alpha1 blocker for 1 week. Results The mean operative time of group A was significantly longer than group B. The incidences of hematuria, flank/abdominal pain, frequency/urgency after surgery were statistically different between both groups. The stone-free rate of each group was 100%. Conclusions The effect of alpha1-adrenergic antagonists is more significant than indwelling stent after ureteroscopic lithotripsy in treating uncomplicated lower ureteral stones.


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Adulto Joven , Sulfonamidas/uso terapéutico , Litotricia/métodos , Cálculos Ureterales/cirugía , Ureteroscopía/métodos , Antagonistas de Receptores Adrenérgicos alfa 1/uso terapéutico , Complicaciones Posoperatorias , Periodo Posoperatorio , Dimensión del Dolor , Estudios Prospectivos , Reproducibilidad de los Resultados , Resultado del Tratamiento , Estadísticas no Paramétricas , Láseres de Estado Sólido/uso terapéutico , Tempo Operativo , Tamsulosina , Tiempo de Internación , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA